Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir. Foscarnet-resistant isolates with DNA polymerase mutations in regions II, VI, and between I and VII were also associated with an important decrease in susceptibility to adefovir (mean IC50 increase: 4.6-fold compared to pre-foscarnet or wild-type isolates) suggesting that adefovir-resistant HSV could be selected in vivo by foscarnet therapy.
Bestman-Smith
Julie
J
Centre de Recherche en Infectiologie of the Centre Hospitalier Universitaire de Québec (Pavillon CHUL), and Universiteé Laval, Québec, Canada.
Boivin
Guy
G
D017088:AIDS-Related Opportunistic Infections / Q000821:virology*; D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017245:Foscarnet / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D006558:Herpes Genitalis / Q000821:virology*; D006561:Herpes Simplex / Q000821:virology*; D018259:Herpesvirus 1, Human / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D018258:Herpesvirus 2, Human / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D017245:Foscarnet; C053001:adefovir; D000225:Adenine